1. Home
  2. BIAF

BIAF

bioAffinity Technologies Inc.

Logo bioAffinity Technologies Inc.

Health Care

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Nasdaq

as 04-18-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Founded: 2014 Country:
United States
United States
Employees: N/A City: SAN ANTONIO
Market Cap: 33.5M IPO Year: 2022
Target Price: N/A AVG Volume (30 days): 213.7K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.91 EPS Growth: N/A
52 Week Low/High: $0.95 - $3.62 Next Earning Date: 05-13-2024
Revenue: $2,532,499 Revenue Growth: 52627.44%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: